Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +210,975.57%
#2 Beta Finance Beta Finance +8,979.03%
#3 Tribe Tribe +73.83%
#4 Orochi Network Orochi Network +53.40%
#5 Chainbase Chainbase +40.85%
#6 BabyBoomToken BabyBoomToken +34.25%
#7 Block Street Block Street +31.59%
#8 Chrema Coin Chrema Coin +28.62%
#9 Freysa AI Freysa AI +26.78%
#10 B3 (Base) B3 (Base) +25.98%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Classificação em ações #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Preço da ação
$0.00244926
Valor de mercado
$51.67K
Variação (1 dia)
5.88%
Variação (1 ano)
110.15%
País
GB
Negociar Nuformix plc (NFX)

Categoria

Healthcare
Receita da Nuformix plc (NFX)
Receita em Sep 2025 TTM: 0.00
De acordo com os últimos relatórios financeiros da Nuformix plc, a receita atual da empresa (TTM) é 0.00. Em 2024, a empresa obteve uma receita de 0.00 igual a a receita do ano 2023, que foi de 0.00. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Nuformix plc de 2014 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU